Alfa Cytology provides comprehensive technical support for radiopharmaceutical development through customized radiolabeling and physicochemical characterization services.
NEW YORK, NY, June 18, 2026 /24-7PressRelease/ — As the development of targeted radiopharmaceuticals and antibody-drug conjugates (ADCs) continues to accelerate, Alfa Cytology has recently further enhanced its radiopharmaceutical development service portfolio. By integrating its custom radiolabeling for ADCs and targeted radiopharmaceuticals services with Radiopharmaceutical Physicochemical Characterization CRO services, the company provides more comprehensive research and development support for biotechnology companies, pharmaceutical companies, and scientific research institutions.
In recent years, radiopharmaceuticals have become an important area of research in precision medicine. From cancer diagnosis to targeted therapy, an increasing number of research projects are utilizing radiolabeling technologies for pharmacokinetic studies, biodistribution analysis, and molecular imaging applications. At the same time, the rapid development of ADCs, peptide therapeutics, and targeted small molecules has created growing demand for advanced radiopharmaceutical development capabilities.
However, successful completion of radiolabeling does not mark the end of development. Key attributes of radiolabeled candidates, including radiochemical purity, stability, lipophilicity, and target-binding capability, still require further evaluation. How to obtain high-quality radiolabeled products while systematically assessing their critical quality attributes has become an important consideration in radiopharmaceutical development.
In order to meet this demand, Alfa Cytology continues to strengthen its radiopharmaceutical development technology platforms by integrating radiolabeling and physicochemical characterization capabilities, providing researchers with more comprehensive and coordinated research support. By covering key research activities from radiolabeling to the assessment of critical quality attributes, the company aims to help customers generate reliable data for candidate evaluation and subsequent studies, thereby improving development efficiency and reducing uncertainty throughout the research process.
In radiolabeling, Alfa Cytology provides custom radiolabeling for ADCs and targeted radiopharmaceuticals services, supporting the radiolabeling of antibodies, ADCs, peptide therapeutics, small molecules, and other targeted compounds. The service supports a variety of radionuclides used in diagnostic and therapeutic applications. These services can be applied to pharmacokinetic studies, biodistribution analysis, molecular imaging, and radiopharmaceutical development.
At the same time, Alfa Cytology also provides radiopharmaceutical physicochemical characterization CRO services, covering the analysis of key parameters including radiochemical purity, stability, lipophilicity (LogP/LogD), and immunoreactivity. Through systematic physicochemical characterization studies, research teams can more comprehensively evaluate candidate properties and generate reliable data to support subsequent research activities.
“The demand for high-quality radiolabeling and physicochemical characterization data continues to grow as radiopharmaceutical development advances,” said a spokesperson for Alfa Cytology. “By integrating our technical capabilities, we aim to provide customers with more efficient research support and help advance the development of innovative radiopharmaceuticals and targeted therapies.”
About Alfa Cytology
Alfa Cytology is a professional service provider focused on biomedical research and development support. The company provides professional research services for scientific research institutions, biotechnology companies, and pharmaceutical organizations. Its service portfolio covers radiopharmaceutical development, drug discovery, preclinical research, and related biotechnology services, supporting the advancement and translation of innovative therapies.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
